Key terms
About LRMR
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LRMR news
Apr 03
9:14am ET
Leerink bullish on Larimar Therapeutics, initiates with an Outperform
Apr 03
8:02am ET
Larimar Therapeutics initiated with an Outperform at Leerink
Mar 18
8:35am ET
5 Stocks that Analysts Love in March 2024
Mar 15
4:15pm ET
Buy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug Nomlabofusp
Mar 14
4:21pm ET
Larimar Therapeutics provides update on nomlabofusp development
Mar 14
4:18pm ET
Larimar Therapeutics reports Q4 EPS (30c), consensus (25c)
Mar 12
8:25am ET
Buy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s Ataxia
Mar 12
6:09am ET
3 Best Stocks to Buy Now, 3/12/2024, According to Top Analysts
Mar 12
12:40am ET
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)
Mar 11
4:26pm ET
Larimar Therapeutics doses first patient in nomlabofusp study
Mar 05
8:45am ET
Largest borrow rate increases among liquid names
Feb 20
7:55pm ET
Buy Rating Affirmed: Larimar Therapeutics’ Nomlabofusp Shows Potential in Friedreich’s Ataxia Treatment
Feb 19
2:08am ET
Insider Trading: Larimar’s (NASDAQ:LRMR) Director Makes an Enormous Purchase
Feb 16
4:27pm ET
Larimar Therapeutics Secures $161.8M from Public Offering
Feb 14
6:19am ET
Larimar Therapeutics 17.2M share Spot Secondary priced at $8.74
Feb 13
4:23pm ET
Larimar Therapeutics files common stock, warrants offering
Feb 13
5:08am ET
Buy Rating Affirmed on Larimar Therapeutics Amid Promising Clinical Trial Results and Accelerated Approval Pathway
Feb 13
4:59am ET
Buy Rating Affirmed: Larimar Therapeutics’ Promising Drug Advances on Regulatory and Efficacy Fronts
Feb 12
7:03pm ET
Larimar Therapeutics price target raised to $10 from $4.50 at Citi
Feb 12
8:24am ET
Larimar Therapeutics Announces Successful Phase 2 Nomlabofusp Study
Feb 12
8:12am ET
Larimar Therapeutics Reports Positive Phase 2 Results, Updates Investor Resources
Feb 12
8:09am ET
Larimar Therapeutics Phase 2 Success in Friedreich’s Ataxia Trial
Feb 12
7:13am ET
Larimar Therapeutics expects cash to provide runway into 1Q25
Feb 12
7:12am ET
Larimar reports topline data from Phase 2 dose exploration study of nomlabofusp
Jan 31
2:50pm ET
William Blair biotech analyst to hold an analyst/industry conference call
Jan 31
4:55am ET
William Blair biotech analyst to hold an analyst/industry conference call
Jan 30
12:44pm ET
William Blair biotech analyst to hold an analyst/industry conference call
No recent press releases are available for LRMR
LRMR Financials
Key terms
Ad Feedback
LRMR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LRMR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range